Literature DB >> 27995948

Liver cancer: Regorafenib - a new RESORCE in HCC.

David Killock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27995948     DOI： 10.1038/nrclinonc.2016.214

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321
  1 in total
  3 in total

Review 1.  The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma.

Authors:  Zhongguang Chen; Lili Jiang; Lifan Liang; Kelly Koral; Qian Zhang; Lei Zhao; Songjian Lu; Junyan Tao
Journal:  Am J Pathol       Date:  2021-05-14       Impact factor: 5.770

2.  Prediction and analysis of weighted genes in hepatocellular carcinoma using bioinformatics analysis.

Authors:  Qifan Zhang; Shibo Sun; Chen Zhu; Yujian Zheng; Qing Cai; Xiaolu Liang; Haorong Xie; Jie Zhou
Journal:  Mol Med Rep       Date:  2019-02-04       Impact factor: 2.952

3.  Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.

Authors:  Jun Arai; Yumi Otoyama; Ken-Ichi Fujita; Kaku Goto; Masayuki Tojo; Atsushi Katagiri; Hisako Nozawa; Yutaro Kubota; Takehiro Takahashi; Hiroo Ishida; Takuya Tsunoda; Natsumi Matsumoto; Keita Ogawa; Ryo Nakagawa; Ryosuke Muroyama; Naoya Kato; Hitoshi Yoshida
Journal:  BMC Cancer       Date:  2022-04-20       Impact factor: 4.638
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.